Completed OBSERVATIONAL NCT05172180

Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19 (CARECOVID)

Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

Conditions COVID-19

Interventions Reamberin Ringer's solution

Updated 6 times since 2022 Last updated: Dec 16, 2024 Started: Dec 1, 2020 Primary completion: Jan 31, 2021 Completion: Apr 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates COVID-19 and is currently completed. POLYSAN Scientific & Technological Pharmaceutical Company leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed
Jan 2025 — Sep 2025 [monthly]

Completed
Sep 2024 — Jan 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2024 — Jul 2024 [monthly]

Completed

▶ Show 1 earlier version

Jan 2022 — Jan 2024 [monthly]

Completed

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

POLYSAN Scientific & Technological Pharmaceutical Company

Data source: POLYSAN Scientific & Technological Pharmaceutical Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nizhny Novgorod, Russia